Literature DB >> 21746827

The backlash against bioequivalence and the interchangeability of brand-name and generic drugs.

Aaron S Kesselheim1.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21746827      PMCID: PMC3168615          DOI: 10.1503/cmaj.110808

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy.

Authors:  K Liow; G L Barkley; J R Pollard; C L Harden; C W Bazil
Journal:  Neurology       Date:  2007-04-17       Impact factor: 9.910

2.  Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.

Authors:  Barbara M Davit; Patrick E Nwakama; Gary J Buehler; Dale P Conner; Sam H Haidar; Devvrat T Patel; Yongsheng Yang; Lawrence X Yu; Janet Woodcock
Journal:  Ann Pharmacother       Date:  2009-09-23       Impact factor: 3.154

3.  Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations.

Authors:  Meytal A Tsadok; Cynthia A Jackevicius; Elham Rahme; Vidal Essebag; Mark J Eisenberg; Karin H Humphries; Jack V Tu; Hassan Behlouli; Jennifer Joo; Louise Pilote
Journal:  CMAJ       Date:  2011-07-11       Impact factor: 8.262

4.  Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias.

Authors:  J A Reiffel; P R Kowey
Journal:  Am J Cardiol       Date:  2000-05-01       Impact factor: 2.778

5.  The consequences of requesting "dispense as written".

Authors:  William H Shrank; Joshua N Liberman; Michael A Fischer; Jerry Avorn; Elaine Kilabuk; Andrew Chang; Aaron S Kesselheim; Troyen A Brennan; Niteesh K Choudhry
Journal:  Am J Med       Date:  2011-04       Impact factor: 4.965

6.  Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs.

Authors:  Scott T Devine; Edmond Weisbart; John Barron; Andrew Behm
Journal:  Curr Med Res Opin       Date:  2010-02       Impact factor: 2.580

Review 7.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Alexander S Misono; Joy L Lee; Margaret R Stedman; M Alan Brookhart; Niteesh K Choudhry; William H Shrank
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272

8.  The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.

Authors:  William H Shrank; Tuyen Hoang; Susan L Ettner; Peter A Glassman; Kavita Nair; Dee DeLapp; June Dirstine; Jerry Avorn; Steven M Asch
Journal:  Arch Intern Med       Date:  2006-02-13

9.  The risks and costs of multiple-generic substitution of topiramate.

Authors:  M S Duh; P E Paradis; D Latrémouille-Viau; P E Greenberg; S P Lee; M B Durkin; G J Wan; M F T Rupnow; J LeLorier
Journal:  Neurology       Date:  2009-06-16       Impact factor: 9.910

  9 in total
  4 in total

1.  Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Authors:  Daniel M Hartung; Luke Middleton; Leanne Svoboda; Jessina C McGregor
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

2.  Impact of brand-name drug worship and expectation psychology on antidepressant efficacy.

Authors:  Jian Cai; Meirong Ye; Chunhua Fei; Feng Xu
Journal:  Int J Clin Exp Med       Date:  2013-09-01

3.  Population Pharmacokinetics of Levetiracetam: A Systematic Review.

Authors:  Zi-Ran Li; Chen-Yu Wang; Xiao Zhu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

4.  China's new policy for healthcare cost-control based on global budget: a survey of 110 clinicians in hospitals.

Authors:  Jianzhou Yan; Hui-Heng Lin; Dan Zhao; Yuanjia Hu; Rong Shao
Journal:  BMC Health Serv Res       Date:  2019-02-01       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.